Apitope Technology Ltd. (Bristol, UK),  has announced the completion of dosing for all six multiple sclerosis (MS)  patients in a Phase 1/2a trial of ATX-MS-1467. The therapeutic vaccine was  found to be safe and well tolerated in secondary progressive multiple sclerosis  (SPMS) patients.

  Although efficacy was not an  endpoint of this trial, one patient, with optic neuritis resulting from the  neuroinflammatory process involved in MS, did demonstrate a clinically significant  improvement in visual acuity post treatment. This was demonstrated in analysis  of the initial visual acuity examination at screening compared to the one-month  follow up test.

  The ATX-MS-1467 Phase 1/2a open  label trial was designed as a dose-escalation study to assess the safety and  tolerability with all six patients receiving five escalating doses given seven  to 14 days apart of 25, 50, 100, 400, and 800 µg followed by a repeat of the  800 µg dose.

News

Apitope Technology Ltd. (Bristol, UK), has announced the completion of dosing for all six multiple sclerosis (MS) patients in a Phase 1/2a trial of ATX-MS-1467